ATE353906T1 - Cd27 ligand - Google Patents

Cd27 ligand

Info

Publication number
ATE353906T1
ATE353906T1 AT93920446T AT93920446T ATE353906T1 AT E353906 T1 ATE353906 T1 AT E353906T1 AT 93920446 T AT93920446 T AT 93920446T AT 93920446 T AT93920446 T AT 93920446T AT E353906 T1 ATE353906 T1 AT E353906T1
Authority
AT
Austria
Prior art keywords
cd27l
ligand
polypeptide
vectors
receptor
Prior art date
Application number
AT93920446T
Other languages
English (en)
Inventor
M Patricia Beckmann
Raymond G Goodwin
Judith G Giri
Richard J Armitage
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE353906T1 publication Critical patent/ATE353906T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Luminescent Compositions (AREA)
  • Registering, Tensioning, Guiding Webs, And Rollers Therefor (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT93920446T 1992-09-08 1993-09-01 Cd27 ligand ATE353906T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94164892A 1992-09-08 1992-09-08
US08/106,507 US5573924A (en) 1992-09-08 1993-08-13 CD27 ligand

Publications (1)

Publication Number Publication Date
ATE353906T1 true ATE353906T1 (de) 2007-03-15

Family

ID=26803747

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93920446T ATE353906T1 (de) 1992-09-08 1993-09-01 Cd27 ligand

Country Status (9)

Country Link
US (1) US5573924A (de)
EP (1) EP0662077B1 (de)
JP (1) JP3559281B2 (de)
AT (1) ATE353906T1 (de)
AU (1) AU5099293A (de)
CA (1) CA2144056C (de)
DE (1) DE69334111T2 (de)
ES (1) ES2281896T3 (de)
WO (1) WO1994005691A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) * 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US6599719B2 (en) 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
US6824767B2 (en) 1994-11-07 2004-11-30 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5994503A (en) * 1995-03-27 1999-11-30 Yale University Nucleotide and protein sequences of lats genes and methods based thereon
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6010853A (en) * 1997-05-29 2000-01-04 Dana-Farber Cancer Institute Siva genes, novel genes involved in CD27-mediated apoptosis
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003009862A1 (en) * 2001-07-20 2003-02-06 Genset S.A. Agonists and antagonists of modumet for use in the treatment of metabolic disorders
ES2394018T3 (es) * 2001-11-27 2013-01-15 Ucb Pharma S.A. Procedimientos para el diagnóstico y el tratamiento de cánceres derivados de células epiteliales
US7261892B2 (en) * 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20030166559A1 (en) * 2002-01-04 2003-09-04 Desjarlais John R. Dominant negative proteins and methods thereof
US20040170602A1 (en) * 2002-01-04 2004-09-02 Desjarlais John R. Dominant negative proteins and methods thereof
SG108837A1 (en) * 2002-03-11 2005-02-28 Pi Eta Consulting Co Pte Ltd An enterprise knowledge and information acquisition, management and communications system with intelligent user interfaces
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20050282168A1 (en) * 2003-09-29 2005-12-22 Wyeth Cell surface molecules as markers and therapeutic agents against kidney cancers
US7641903B2 (en) * 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) * 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006044643A2 (en) * 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド ヒト化抗ｃｄ７０結合剤およびその使用
NZ566395A (en) * 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
MX2009006277A (es) * 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
EP2090320A1 (de) 2008-02-15 2009-08-19 Helmholtz-Zentrum für Infektionsforschung GmbH Liganden des natürlichen Killer Zelloberflächenmarkers CD27 und therapeutische Verwendungen davon
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
ES2538122T3 (es) * 2008-07-21 2015-06-17 Apogenix Gmbh Moléculas de una sola cadena de TNFSF
EP2517555A4 (de) 2009-12-25 2014-09-24 Chugai Pharmaceutical Co Ltd Such- und screening-verfahren für ein zielmolekül eines krebsmittels mit einem nichtmenschlichen tiermodell mit darin transplantierter nog-krebszelllinie
JP6230789B2 (ja) 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
EP2686347B1 (de) 2011-03-16 2018-05-02 argenx BVBA Antikörper gegen cd70
EP2749641B1 (de) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Krebsstammzellenisolierung
MX353958B (es) * 2011-09-22 2018-02-07 Amgen Inc Proteinas de union al antigeno cd27l.
EP2772268B8 (de) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Krebsstammzellenspezifisches molekül
NZ629697A (en) 2012-03-15 2017-01-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
JP2018534264A (ja) 2015-09-28 2018-11-22 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞
EP3364995B1 (de) * 2015-10-23 2021-08-04 Apogenix AG Einkettige cd27-rezeptor-agonisten-proteine
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CN116997654A (zh) 2021-03-17 2023-11-03 第一三共株式会社 编码抗乙酰胆碱受体自身抗体的嵌合受体的基因
CN119143876B (zh) * 2024-10-09 2025-09-16 武汉海沙百得生物技术有限公司 一种抗cd27l的全人源抗体或抗体片段及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5573924A (en) * 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
PT672141E (pt) * 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis

Also Published As

Publication number Publication date
CA2144056C (en) 2010-04-13
EP0662077A1 (de) 1995-07-12
JPH08500976A (ja) 1996-02-06
CA2144056A1 (en) 1994-03-17
JP3559281B2 (ja) 2004-08-25
EP0662077A4 (de) 1997-01-08
EP0662077B1 (de) 2007-02-14
DE69334111T2 (de) 2007-11-22
ES2281896T3 (es) 2007-10-01
US5573924A (en) 1996-11-12
AU5099293A (en) 1994-03-29
DE69334111D1 (en) 2007-03-29
WO1994005691A1 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
ATE353906T1 (de) Cd27 ligand
DE69334100D1 (de) Elk ligand, ein cytokin
DE69433552D1 (de) An den zelloberflächenrezeptor hek bindendes cytokin
ATE286907T1 (de) Cytokinin-designiertes lerk-5
AU4639396A (en) Cytokine designated lerk-7
ZA967562B (en) Materials and methods relating to the attachment and display of substances on cell surfaces.
EP1676857A3 (de) Trail bindender Rezeptor
DE69631331D1 (de) Cd40l mutein
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
DE69737978D1 (de) Als 2f1 bezeichnetes rezeptorprotein
IL132496A0 (en) Mammalian cytokine-like factor 7
EP0739350A4 (de) Fas-antigenbindender ligand
DK0745122T3 (da) Galninreceptor, nukleinsyrer, transformerede celler og anvendelser heraf
NO974713L (no) Gener som koder for lymfocyttinterferon-regulatorisk faktor (LSIRF) polypeptider
MX9700213A (es) Citocina novedosa designada como lerk-5.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties